6.10
-0.27 (-4.24%)
| Previous Close | 6.37 |
| Open | 6.01 |
| Volume | 241,807 |
| Avg. Volume (3M) | 280,230 |
| Market Cap | 129,285,224 |
| Price / Sales | 1.97 |
| Price / Book | 1.04 |
| 52 Weeks Range | |
| Earnings Date | 5 Feb 2025 - 10 Feb 2025 |
| Profit Margin | -160.27% |
| Operating Margin (TTM) | -134.58% |
| Diluted EPS (TTM) | -5.48 |
| Quarterly Revenue Growth (YOY) | -4.90% |
| Total Debt/Equity (MRQ) | 151.88% |
| Current Ratio (MRQ) | 4.92 |
| Operating Cash Flow (TTM) | -89.97 M |
| Levered Free Cash Flow (TTM) | -63.27 M |
| Return on Assets (TTM) | -17.18% |
| Return on Equity (TTM) | -59.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Enanta Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.09% |
| % Held by Institutions | 100.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Krensavage Asset Management, Llc | 30 Sep 2024 | 1,498,074 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (JMP Securities, 244.26%) | Buy |
| Median | 20.00 (227.87%) | |
| Low | 18.00 (HC Wainwright & Co., 195.08%) | Buy |
| Average | 19.67 (222.46%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 7.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Dec 2024 | 18.00 (195.08%) | Buy | 6.10 |
| 10 Oct 2024 | 27.00 (342.62%) | Buy | 10.63 | |
| Baird | 26 Nov 2024 | 20.00 (227.87%) | Buy | 8.56 |
| JMP Securities | 26 Nov 2024 | 21.00 (244.26%) | Buy | 8.56 |
| 09 Oct 2024 | 22.00 (260.66%) | Buy | 10.71 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |